• No se han encontrado resultados

[PDF] Top 20 Sorafenib, a systemic therapy for hepatocellular carcinoma

Has 10000 "Sorafenib, a systemic therapy for hepatocellular carcinoma" found on our website. Below are the top 20 most common "Sorafenib, a systemic therapy for hepatocellular carcinoma".

Sorafenib, a systemic therapy for  hepatocellular carcinoma

Sorafenib, a systemic therapy for hepatocellular carcinoma

... protein for virus homing, etc. For most of the CRAds de- scribed to date, the results obtained in tumor lines show highly therapeutic potential; however, in some cases the in vivo evaluations demonstrate ... See full document

12

MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma

MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma

... INTRODUCTION Hepatocellular carcinoma (HCC) is the third- leading cause of cancer-related death worldwide ...applied for advanced HCC [2,3]. Recently, it has been reported that sorafenib, a ... See full document

9

The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib

The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib

... to sorafenib treatment in patients with unre- sectable hepatocellular carcinoma has been indicated as a prognostic factor for survival in a recent prospective ...with sorafenib under ... See full document

6

Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience

Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience

... with hepatocellular carcinoma be- longing to BCLC stage B and C, presenting to the Institute of Liver Diseases and Transplantation, Global Health City, India from August 2010 to October 2014 were included ... See full document

8

Sorafenib en Carcinoma Hepatocelular

Sorafenib en Carcinoma Hepatocelular

... of sorafenib in patientes in the Asia-Pacific region with advanced hepatolcellular carcinoma: A phase III randomized, double blind, placebo-controlled ...of hepatocellular carcinoma: an ... See full document

10

Sorafenib en Carcinoma Hepatocelular

Sorafenib en Carcinoma Hepatocelular

... d. Estudios por imágenes cada 3 meses que permitan evaluar el grado de respuesta según los criterios mRECIST (tomo- grafía computada multidetector con contraste en 4 fases, resonancia magnética nuclear dinámica con ... See full document

10

Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy

Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy

... transplantation being the less used modality and this remained constant throughout the different countries. These findings are similar to those the United States, China, Japan and Europe and likely reflect diagnosis of ... See full document

17

Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases

Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases

...  sowie systemische Therapie mit Multikinase-Inhibitoren (Sorafenib). Als Goldstandard zur Behandlung resektabler HCC gilt heutzutage – unter Berücksichtigung der „Barcelona-Kriterien“ (Child-Pugh class A, Fehlen ... See full document

45

Viral Infection and Hepatocellular Carcinoma

Viral Infection and Hepatocellular Carcinoma

... outcome for hepatocellular ...surgical therapy such as resection and liver transplantation constitute curative ...with sorafenib is the only one FDA-approved first line treatment ...this ... See full document

162

Cancer gene discovery in hepatocellular carcinoma

Cancer gene discovery in hepatocellular carcinoma

... growth factor (VEGF), and fibroblast growth factors (FGFs) as major drivers underlying pro-angiogenic signals in human HCC. VEGF is considered the most potent angiogenic factor in HCC, and it is often found over-expressed ... See full document

9

COMBATING β-CATENIN DRIVEN HEPATOCELLULAR CARCINOMA

COMBATING β-CATENIN DRIVEN HEPATOCELLULAR CARCINOMA

... and for effective metabolism ...drug Sorafenib for stage IV unresectable HCC is its impact on angiogenesis through inhibition of certain receptor tyrosine kinases such as VEGFR2 (Flk1), platelet ... See full document

155

Lactate Dehydrogenase Is an Important Prognostic Indicator for Hepatocellular Carcinoma after Partial Hepatectomy

Lactate Dehydrogenase Is an Important Prognostic Indicator for Hepatocellular Carcinoma after Partial Hepatectomy

... cell carcinoma, and germ cell tumors [7–14] ...with sorafenib and HCC patients undergoing transcatheter arterial chemoembolization (TACE) has been confirmed, the clinical significance of LDH in HCC patients ... See full document

7

Advanced hepatocellular carcinoma  Review of targeted molecular drugs

Advanced hepatocellular carcinoma Review of targeted molecular drugs

... Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world in terms of incidence, ac- counting for approximately 630 thousand new cases per year; in addition, HCC is the third most ... See full document

7

Molecular and cellular oncogenic mechanisms in hepatocellular carcinoma

Molecular and cellular oncogenic mechanisms in hepatocellular carcinoma

... Despite decades of research into molecularly targeted therapies, including the recent advent of immunotherapy, the armamentarium against HCC is at best discouraging. None of these agents, including sorafenib, have ... See full document

6

Sarcomatous Hepatocellular Carcinoma

Sarcomatous Hepatocellular Carcinoma

... of systemic adjuvant chemotherapy is still under ...recurrence for 12 months after surgery was noted ...this systemic chemotherapy as a standard treatment, frustratingly, there is no better way ... See full document

6

Hepatocellular carcinoma  An overview

Hepatocellular carcinoma An overview

... made for every three months of ...postoperative systemic chemotherapy (adriamycin) added to immuno- suppressive regimens reduces the risk of recurrence after liver ... See full document

10

Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis

Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis

... theory for using preoperative TACE was that HCC tumors frequently invade the portal vein (30-50% in pa- tients with an HCC of 3-5 cm in diameter), leading to intrahepatic metastasis, which is the most common cause ... See full document

9

Hepatocellular carcinoma viral etiology and molecular mechanisms

Hepatocellular carcinoma viral etiology and molecular mechanisms

... Methods for HCV Genotyping Molecular genotyping Because differences in geographical distribution, disease outcome, and response to therapy among HCV genotypes have been suggested, reliable methods ... See full document

118

Hepatocellular carcinoma that arose from primary Sjgrens syndrome

Hepatocellular carcinoma that arose from primary Sjgrens syndrome

... with systemic complications including pulmonary, renal, articular, and muscular involve- ments as well as neuropathies and lymphoma, but liver involvement was not ...and carcinoma, but with no clues ... See full document

6

lncRNA involvement in hepatocellular carcinoma metastasis and prognosis

lncRNA involvement in hepatocellular carcinoma metastasis and prognosis

... including hepatocellular carcinoma (Hu et ...role for GAS5 in the molec- ular etiology of HCC and implicate the poten- tial application of GAS5 in HCC ... See full document

14

Show all 10000 documents...